Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
Globe Newswire•30/09/2026•17:15 ET
0
Key Highlights
- ➤Offering raised approximately $117.1 million in net proceeds for Immix Biopharma (IMMX)
- ➤11,363,637 shares priced at $11.00 each in the underwritten offering
- ➤Proceeds will fund NXC-201 development, working capital and general corporate purposes
- ➤J.P. Morgan acted as sole book-running manager for the offering
LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $117.1 million.
Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes.
Get started
Create a free account to read the full story.